Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cue Biopharma (CUE) Enterprise Value (2017 - 2025)

Cue Biopharma's Enterprise Value history spans 9 years, with the latest figure at -$18.7 million for Q3 2025.

  • For Q3 2025, Enterprise Value changed N/A year-over-year to -$18.7 million; the TTM value through Sep 2025 reached -$18.7 million, down 89.32%, while the annual FY2024 figure was -$22.5 million, 53.98% up from the prior year.
  • Enterprise Value for Q3 2025 was -$18.7 million at Cue Biopharma, down from -$470000.0 in the prior quarter.
  • Across five years, Enterprise Value topped out at -$470000.0 in Q2 2025 and bottomed at -$76.3 million in Q4 2022.
  • The 5-year median for Enterprise Value is -$48.8 million (2023), against an average of -$40.7 million.
  • The largest annual shift saw Enterprise Value tumbled 315.36% in 2024 before it skyrocketed 97.78% in 2025.
  • A 5-year view of Enterprise Value shows it stood at -$52.2 million in 2021, then tumbled by 46.12% to -$76.3 million in 2022, then skyrocketed by 36.03% to -$48.8 million in 2023, then skyrocketed by 53.98% to -$22.5 million in 2024, then grew by 16.73% to -$18.7 million in 2025.
  • Per Business Quant, the three most recent readings for CUE's Enterprise Value are -$18.7 million (Q3 2025), -$470000.0 (Q2 2025), and -$912000.0 (Q1 2025).